Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 9/20 | 0.45 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HTR3A | P46098 | 1/20 | 0.38 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7415267 | 1.00 | DPP4 (0.45) | DPP4ALOX5APTP53HTR3ACACNA1G | |
| SCHEMBL7420850 | 0.98 | DPP4 (0.45) | DPP4ALOX5APTP53HTR3ACACNA1G | |
| SCHEMBL7425954 | 0.96 | DPP4 (0.45) | DPP4ALOX5APTP53HTR3AROCK2 | |
| SCHEMBL7426692 | 0.89 | ALOX5AP (0.43) | DPP4ALOX5APTP53NPC1ALDH1A1 | |
| SCHEMBL7420854 | 0.87 | EDNRA (0.38) | DPP4TP53ALDH1A1KDM4EMEN1 | |
| SCHEMBL7426188 | 0.87 | EDNRA (0.38) | DPP4TP53ALDH1A1KDM4EMEN1 | |
| SCHEMBL7424858 | 0.87 | L3MBTL1 (0.47) | DPP4ALOX5APTP53NPC1ALDH1A1 | |
| SCHEMBL7421847 | 0.86 | ALOX5AP (0.43) | DPP4ALOX5APTP53ALDH1A1KDM4E | |
| SCHEMBL7425177 | 0.86 | ALOX5AP (0.45) | DPP4ALOX5APTP53ALDH1A1L3MBTL1 | |
| SCHEMBL7422738 | 0.85 | EDNRA (0.38) | DPP4ALDH1A1KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0820441-B1 | INDOLE DERIVATIVES AS cGMP-PDE INHIBITORS | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-06-26 | — | — | EP | disclosed |
| US-6358992-B1 | Method of inhibiting neoplastic cells with indole derivatives | CELL PATHWAYS, INC. | 2002-03-19 | — | — | US | disclosed |
| US-6069156-A | Indole derivatives as cGMP-PDE inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-05-30 | — | — | US | disclosed |
| EP-0820441-A1 | INDOLE DERIVATIVES AS cGMP-PDE INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-01-28 | — | — | EP | disclosed |
| WO-1996032379-A1 | INDOLE DERIVATIVES AS cGMP-PDE INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-10-17 | — | — | WO | disclosed |